E. Cho

Evaluation of the efficacy and safety of a 3-weekly TS-1 regimen as adjuvant therapy for stage II and III advanced gastric cancer: A pilot study.
20240 citationsauthor #6
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
20236 citationsauthor #18
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.
20237 citationsauthor #4
EP08.02-025 Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial
20221 citationsauthor #8
LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial
202221 citationsauthor #13
P1.16-01 Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
20226 citationsauthor #4
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia
20220 citationsauthor #4
Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer
20224 citationsauthor #6
126P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer (NSCLC)
20222 citationsauthor #20
Long-term follow-up results of cytarabine-contain-ing chemotherapy for acute promyelocytic leukemia Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia
20220 citationsauthor #4
Subsequent pregnancy and long-term safety after breast cancer: a retrospective analysis of Korean health insurance data
20227 citationsauthor #4
A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16).
20221 citationsauthor #14
148P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)
20223 citationsauthor #7
Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies
202116 citationsauthor #9
A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors.
202165 citationsauthor #5
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
20218 citationsauthor #6
P86.12 Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
20213 citationsauthor #7
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
202125 citationsauthor #59
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.
202163 citationsauthor #5
Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
202013 citationsauthor #13
Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study.
20205 citationsauthor #5
Subsequent pregnancy and long-term safety from breast cancer patients.
20200 citationsauthor #4
Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study.
202010 citationsauthor #5
1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC
202038 citationsauthor #3
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
2020142 citationsauthor #8
Abstract P2-15-11: A phase II trial of genexol-PM and doxorubicin in patients with advanced Her-2 negative breast cancer
20201 citationsauthor #1
ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).
20203 citationsauthor #5
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients.
201967 citationsauthor #5
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
2019106 citationsauthor #12
JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).
201977 citationsauthor #8
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
2019108 citationsauthor #7
Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
20191 citationsauthor #6
Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.
20191 citationsauthor #7
Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing
201919 citationsauthor #6
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC
20197 citationsauthor #7
Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
201946 citationsauthor #8
Osimertinib versus Standard of Care EGFR TKI as First‐Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset
2019126 citationsauthor #12
Left ventricular ejection fraction (LVEF) change for the first 6 months predicts development of trastuzumab-related cardiotoxicity in patients with breast cancer: An implication for the more efficient cardiac surveillance.
20180 citationsauthor #6
Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer
20184,169 citationsauthor #15
Abstract CT113: Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC
20189 citationsauthor #5
JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results.
201816 citationsauthor #4
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
201811 citationsauthor #7
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
201827 citationsauthor #3
YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.
20184 citationsauthor #9
Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)
201819 citationsauthor #5
Prognostic significance of cachexia score assessed by CT in male patients with small cell lung cancer
201828 citationsauthor #6
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
2018636 citationsauthor #5
The effect of post-operative chemotherapy and prognostic factors for colorectal cancer liver: Only metastasis (CRLM) after R0 or R1 resection.
20170 citationsauthor #9
CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study.
201738 citationsauthor #6
114PPhase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea
20170 citationsauthor #1
Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
201729 citationsauthor #13
LBA6_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset
20173 citationsauthor #13
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second‐Line Treatment of Advanced Non–Small‐Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
201710 citationsauthor #7
P3.02b-053 A Randomized, Open Label, Phase II Study Comparing Pemetrexed plus Cisplatin versus Pemetrexed Alone in EGFR Mutant NSCLC after EGFR-TKI: QOL Data: Topic: EGFR Clinical
20170 citationsauthor #6
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
20178 citationsauthor #2
P2.03a-037 Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy: Topic: Clinical Trials
20170 citationsauthor #6
MA07.07 Ceritinib in ROS1-Rearranged Non-Small-Cell Lung Cancer: An Update of Korean Nationwide Phase II Study
20171 citationsauthor #8
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
2017274 citationsauthor #7
413OOsimertinib vs standard of care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA
20171 citationsauthor #11
Use of a cognitive computing system for treatment of colon and gastric cancer in South Korea.
201712 citationsauthor #11
Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.
20170 citationsauthor #2
442PSafety of nivolumab in patients with advanced or metastatic non-small cell lung cancer who have received at least one prior systemic regimens: Expanded access program in Korea (ONO-4538-X04)
20170 citationsauthor #13
P2.03a-038 Phase III Trial of Pemetrexed/Carboplatin vs Pemetrexed Only in Chemo-Naïve Elderly Non-SQCC NSCLC Patients Aged ≥ 70: Topic: Clinical Trials
20170 citationsauthor #3
LBA2_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
201736 citationsauthor #11
Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
201647 citationsauthor #3
Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy
201651 citationsauthor #8
Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant‐specific inhibitor, in T790M‐positive NSCLC at the recommended phase II dose: 1300
201634 citationsauthor #6
Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non-small cell lung cancer and good performance status.
20160 citationsauthor #2
Ceritinib in ROS1-rearranged non-small-cell lung cancer: a Korean nationwide phase II study
201611 citationsauthor #8
Neutrophil-Lymphocyte Ratio Predicts Survival in Terminal Cancer Patients
201614 citationsauthor #5
Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer
201649 citationsauthor #13
A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13.
20162 citationsauthor #6
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
201611 citationsauthor #15
Prognostic significance of CT-emphysema score in patients with advanced squamous cell lung cancer.
201623 citationsauthor #4
Treatment of Advanced and Metastatic Squamous Non-small Cell Lung Cancer
20160 citationsauthor #1
BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.
201645 citationsauthor #13
Evaluation of sarcopenia in small-cell lung cancer patients by routine chest CT
201671 citationsauthor #5
★[High Score]Craniopharyngiomas in korean children and adolescents: systematic analysis of 49 cases with long-term follow-up in one center
20160 citationsauthor #1
Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma
201615 citationsauthor #7
East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)
201619 citationsauthor #3
An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer
201690 citationsauthor #9
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
2016141 citationsauthor #11
Safety of eribulin in Korean patients with metastatic breast cancer.
20154 citationsauthor #15
A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09
201522 citationsauthor #8
Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).
201558 citationsauthor #12
Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer
2015199 citationsauthor #5
Abstract A1-21: NOTCH 1 and NOTCH 3 expressions for early stage of non-small cell lung cancer
20150 citationsauthor #1
Abstract P3-10-04: A open-label, randomized, parallel, phase III trial to evaluate the efficacy and safety of Genexol®-PM compared to Genexol®(conventional paclitaxel with cremorphor EL) in recurrent or metastatic breast cancer patients
20152 citationsauthor #10
Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy.
201527 citationsauthor #7
Abstract P3-12-07: A multicenter randomized double-blind phase III clinical trial to evaluate the efficacy and safety of GCPGC, a novel pegylated G-CSF in patients receiving DA or TAC chemotherapy for breast cancer compared to peg-filgrastim
20150 citationsauthor #5
Pre-treatment blood inflammatory markers as predictors of systemic infection during induction chemotherapy: results of an exploratory study in patients with acute myeloid leukemia
20158 citationsauthor #6
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
2015394 citationsauthor #9
Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI.
20155 citationsauthor #14
Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB–IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC).
20153 citationsauthor #9
Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study
201510 citationsauthor #8
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.
2015224 citationsauthor #5
P0091 A pilot study of low-dose capecitabine plus trastuzumab as first-line treatment in patients aged 75 years or older with HER2-positive advanced gastric cancer
20150 citationsauthor #7
Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
20150 citationsauthor #4
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
201518 citationsauthor #2
A phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in Korean patients with advanced or metastatic lung adenocarcinoma who have acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
20150 citationsauthor #6

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT